Viking Therapeutics (VKTX) Enterprise Value (2015 - 2026)

Viking Therapeutics has reported Enterprise Value for 13 years, with the latest figure at -$501.7 million in Q2 2026.

• Quarterly Enterprise Value rose 37.89% year-over-year to -$501.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$501.7 million (up 37.89% YoY) and the FY2025 annual result came in at -$705.7 million, up 21.81% from the prior year.
• Enterprise Value improved to -$501.7 million in Q2 2026 per VKTX's latest filing, from -$603.0 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$135.7 million in Q1 2023 and troughed at -$963.0 million in Q1 2024.
• A 5-year average of -$564.3 million and a median of -$552.3 million in 2026 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 61.35% in 2023, then tumbled 609.82% in 2024.
• Over 5 years, Enterprise Value stood at -$155.5 million in 2022, then sank by 132.87% to -$362.1 million in 2023, then plunged by 149.29% to -$902.6 million in 2024, then increased by 21.81% to -$705.7 million in 2025, then climbed by 28.92% to -$501.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$501.7 million, -$603.0 million, and -$705.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.